Consistent with the synthetic lethal mechanism, the deletion in exons 25 and 26 that removes palmitoylated cysteine 1025 in lung cancer patients was also found to be mutually exclusive from activating Kras mutations [30]. This evidence concerns the gene KRAS and lung carcinoma.